Industry Experts

Anna Dudkina is the Director, Analytical Development at Tessera Therapeutics, where she leads analytical strategies to support the advancement of cutting-edge gene writing technologies. With over two decades of experience in analytical sciences, Anna has held key roles at Merck, Teva Pharmaceuticals, Janssen, and GreenLight Biosciences, contributing to the development of biologics including KEYTRUDA™, AJOVY™, and REMICADE®. Her expertise spans method development and validation, regulatory compliance, technology transfer, and team leadership. Anna holds deep technical knowledge in mass spectrometry, SFC, cIEF, and a range of biochemical and biophysical techniques, making her a pivotal figure in analytical CMC innovation for next-generation therapeutics.